Destiny Pharma PLC Posting of Annual Report and Notice of AGM (5895X)
April 26 2023 - 11:10AM
UK Regulatory
TIDMDEST
RNS Number : 5895X
Destiny Pharma PLC
26 April 2023
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Posting of Annual Report and Accounts, and Notice of AGM
Brighton, United Kingdom - 26 April 2023 - Destiny Pharma plc
(AIM: DEST) a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent
life-threatening infections, announces that the following documents
are now available on the Company's website at
www.destinypharma.com
-- Annual Report and Accounts of the Company for the year ended 31 December 2022
-- Notice of the 2023 Annual General Meeting ("AGM") and details
for voting by proxy, which is to be held at 11.00 a.m. on 25 May
2023 at the offices of finnCap Ltd, One Bartholomew Close, London,
EC1A 7BL
Printed copies of both documents will be posted to shareholders
today.
In order to ensure that shareholders are able to follow the
proceedings of the AGM without attending in person, the Company
will provide access online via the Investor Meet Company platform.
However, please note that shareholders will not be able to vote
online at the AGM via the platform and are therefore requested to
submit their votes via proxy, as early as possible. Shareholders
are invited to submit any questions for the Board to consider.
Questions can be pre submitted ahead of the AGM via the Investor
Meet Company Platform up until 9 a.m. the day before the AGM or
submitted at any time during the AGM itself.
Shareholders that wish to attend the AGM remotely should
register for the event in advance by using the following link:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper
+44 (0) 7931 5000 66
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
Stern IR - US
Janhavi Mohite
+1-212-362-1200
janhavi.mohite@sternir.com
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has completed a positive Phase 2 clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections
including MRSA. It is also co-developing SPOR-COV (TM) , a novel,
biotherapeutic product for the prevention of COVID-19 and other
viral respiratory infections and has earlier grant funded XF drug
research projects.
For further information on the Company, please visit
www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAIFMATMTMTBRJ
(END) Dow Jones Newswires
April 26, 2023 11:10 ET (15:10 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2024 to Jun 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Jun 2023 to Jun 2024